Related references
Note: Only part of the references are listed.Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors: Practical Recommendations for Diagnosis and Clinical Management
Romualdo Barroso-Sousa et al.
CANCER (2018)
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens A Systematic Review and Meta-analysis
Romualdo Barroso-Sousa et al.
JAMA ONCOLOGY (2018)
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
J. C. Osorio et al.
ANNALS OF ONCOLOGY (2017)
Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms
Danae A. Delivanis et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Hypopituitarism and hypothyroidism following atrioventricular block during nivolumab treatment
Tomoko Oda et al.
JOURNAL OF DERMATOLOGY (2017)
Primary hypothyroidism and isolated ACTH deficiency induced by nivolumab therapy: Case report and review
Mei Fang Zeng et al.
MEDICINE (2017)
Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study
Ichiro Yamauchi et al.
THYROID (2017)
Tremelimumab-Induced Graves Hyperthyroidism
Earn H. Gan et al.
EUROPEAN THYROID JOURNAL (2017)
Nivolumab-induced hypothyroidism and selective pituitary insufficiency in a patient with lung adenocarcinoma: a case report and review of the literature
Myrto Kastrisiou et al.
ESMO OPEN (2017)
Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
Jeroen de Filette et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Treatment of Ipilimumab Induced Graves' Disease in a Patient with Metastatic Melanoma
Umal Azmat et al.
CASE REPORTS IN ENDOCRINOLOGY (2016)
Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not)
Salvatore Maria Corsello et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs
Francesco Torino et al.
THYROID (2013)